We’ve had an exciting summer at Insight Medbotics. Our team has achieved several new milestones, which include completing a new robotics system in the urology space.
Designed for MRI compatibility while improving the standard of precision in prostate cancer care, this robotics system offers urologists intuitive MRI access to address the guesswork of traditional ultrasound guidance. Our approach integrates hardware and the digitization of an entire care pathway, which can offer new data-driven clinical insight in ways that haven’t been possible before.
CEO Fazila Seker, Chief Product Officer Akshay Puli and Chief Technology Officer Abhijit Saxena attended the American Urological Association’s 2025 Annual Meeting in Las Vegas, NV, to connect with practicing urologists across care settings.
“The robot’s gathering enthusiastic interest from those who have seen its capabilities and can envision how it would benefit their patients and practice,” says Seker, who is also a member of the Insight Medbotics Board of Directors. “They’re confident in the quick, precise, needle-based procedures our robotics system would facilitate, such as biopsies and focal therapies."
Eliminating the need to translate MRI images to ultrasound would also reduce a lot of guesswork, providing clinicians and patients with greater assurance. In addition, using our MRI robot to guide the needle rather than traditional ultrasound eliminates the need for a rectal probe, a procedure many patients find uncomfortable and may wish to avoid.
For example, Dr. Alexander Kutikov, chair of the Department of Urology at Temple Health’s Fox Chase Cancer Center said, “The robot knows exactly where in the prostate the biopsies were taken from, so it and when focal therapy is delivered, it would be directed precisely at the site of the cancer. That’s incredibly powerful.”
CEO Fazila Seker gives keynote at clinical engineering event
On May 28, CEO Fazila Seker gave the keynote talk at the Joint Conference of the Canadian Medical and Biological Engineering Society (CMBEC47) and the Atlantic Canada Clinical Engineering Society (ACCES26) in Fredericton, NB.
Titled “From PhD to Medtech CEO: Untold stories of the road less traveled,” Fazila described her journey from a PhD in Chemistry to a MedTech entrepreneur.
She also outlined how she builds winning team cultures: “Engineers and scientists sometimes struggle to chart a path from their technical expertise to commercial leadership roles,” says Seker. “Using my own career as an example, this talk demystifies the journey and highlights the skills most important for a successful career in industry.”
During the conference’s lunch session, Fazila also spoke on a panel about, “Women in STEM: Empowering equity-deserving groups to foster innovation.”
Dr. Edward Matsumoto joins our Board of Directions
On July 23, Dr. Edward Matsumoto, a urology expert whose clinical practice uses advanced, minimally-invasive approaches in urologic surgery such as laparoscopic and robotically assisted laparoscopic techniques joined our board of directors. He is a staff urologist at the McMaster Institute of Urology, part of St. Joseph’s Healthcare in Hamilton, ON.
“As a urologist, I’m excited about Insight Medbotics’ approach to combining minimally invasive surgery with MR imaging and artificial intelligence tools,” Matsumoto said in the announcement. “I seek innovations that promise to benefit my patients, and I appreciate their intelligent approach to targeting cancer, the advanced state of their beta device, and how intuitive their software is to use. Joining the board offers influence over this promising technology’s evolution and the less invasive procedures that could benefit prostate cancer patients while advancing a made-in-Canada solution.”
Given our new focus on bringing precision to prostate cancer care, having a clinical leader like Matsumoto on the board brings real-world clinical experience to our existing board, who have deep commercial experience.
“Opportunities to work with clinicians and patients whose needs drive our design decisions is a tremendous gift,” says Seker. “Dr. Edward Matsumoto is a key opinion leader and prolific innovator seeking to advance the standard of care for urology patients through new technology and surgical education. I’m honoured that he shares our excitement about the potential MRI-compatible robotics hold for advancing precision in prostate cancer care. ”
We’ve joined NVIDIA Inception
On August 27, Insight Medbotics announced that we’ve joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements. NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment.
“Participating in the NVIDIA Inception program will help us to access a global network of investors who understand the robotics market as we advance our MRI-compatible robotics technology to market,” says Seker. “Our approach integrates hardware and the digitization of an entire care pathway, which may offer new data-driven clinical insight in ways that haven’t been possible before. Participating in the program will also give our team opportunities to collaborate with NVIDIA’s industry-leading robotics experts and other AI-driven organizations in their ecosystem.”
